Therapeutic effect of two strategies directed at disruption of pathogenic neutrophil extracellular vesicles in a murine emphysema model.

Chronic obstructive pulmonary disease (COPD) is characterized by lung extracellular matrix (ECM) remodeling which contributes to obstruction. This is driven, in part by extracellular vesicles (EVs) from activated neutrophils (PMNs), which express on their surface an α-1 antitrypsin (AAT) insensitive form of neutrophil elastase (NE). These EVs are predicted to bind to collagen fibers via Mac-1 integrins, during which time NE can enzymatically degrade the collagen. Protamine sulfate (PS), a cationic compound used safely for decades in humans, has been shown, in vitro, to dissociate this NE from the EV surface, rendering it AAT-sensitive. Additionally, a nonapedtide inhibitor , MP-9, has been shown to prevent EV association with collagen. We sought to test whether PS, MP-9, or a combination of the two could effectively prevent NE+ EV driven ECM remodeling in an animal COPD model. EVs were preincubated with PBS, protamine sulfate (25uM), MP-9 (50uM), or combination of PS and MP-9. These were delivered intratracheally to anesthetized female 10-12 week old A/J mice for a 7 day time period. One group of mice were sacrificed and lungs sectioned for morphometry, the other group used for live pulmonary function testing. The effect of alveolar destruction by activated neutrophil EVs was abrogated by pretreatment with PS or MP-9. However, in pulmonary function tests, only the PS groups (and combined PS/MP-9 groups) returned pulmonary function to near control levels. These data presented here offer an insight into the effective use of PS in therapeutic setting for EV derived alveolar damage.